Ensysce Biosciences, Inc. (ENSC): Nasdaq/NYSE listing notice — Ensysce receives Nasdaq bid-price deficiency notice; 180-day cure period until July 26, 2023

Ensysce Biosciences, Inc.

Received Nasdaq deficiency letter on Jan 27, 2023 for bid price closing below $1.00 for 30 consecutive business days.
Has until July 26, 2023 to regain compliance; stock must close at $1.00+ for at least 10 business days.
Similar deficiency was cured in Nov 2022 via a 1-20 reverse stock split; new non-compliance now also exists.
Separate MVLS deficiency hearing held Jan 26, 2023; delisting stayed pending Panel decision with possible extension to June 12, 2023.
Common stock continues to trade on Nasdaq under ENSC; no immediate delisting effect.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Ensysce Biosciences, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

January 27, 2023, Ensysce Biosciences Inc. (the “Company”) received a notice in the form of a letter (the “Deficiency Letter”) from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price for the Company’s common stock had closed below $1.00 per share for the previous 30 consecutive business days. In accordance with Nasdaq listing rule 5810(c)(3)(A), the Company has 180 calendar days, or until July 26, 2023, to regain compliance. The Deficiency Letter states that t

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Ensysce Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-003036

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.